NCT00307528View on ClinicalTrials.gov

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

January 20, 2004

Primary Completion Date

March 30, 2005

Study Completion Date

March 30, 2005

Conditions
Prophylaxis Invasive Pneumococcal Diseases and Pneumonia
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK513026

Two-dose intramuscular injection. Five different formulations, each administered to one Group

BIOLOGICAL

Pneumovax 23™

Single dose intramuscular injection.

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00307528 - Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population | Biotech Hunter | Biotech Hunter